To receive all of Mauna Kea Technologies’ financial information in real time, send a request by e-mail to [email protected].
Paris and Boston, September 20, 2022 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary platform for confocal laser endomicroscopy by miniprobe and by needle (p/nCLE), announces the postponement of the publication of its 2022 half-year results, initially scheduled for September 22, 2022, by October 31, 2022 at the latest.
This shift results from the reassignment of the management teams necessary for the implementation of the previously announced joint venture between Mauna Kea Technologies and Tasly Pharmaceutical.
The company will release its new financial calendar shortly.